STME
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System fo… Read more
STME (STME) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2025: 0.048x
Based on the latest financial reports, STME (STME) has a cash flow conversion efficiency ratio of 0.048x as of November 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-74.14K) by net assets ($-1.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
STME - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how STME's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
STME Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STME ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADS Maritime Holding Plc
OL:ADS
|
-0.043x |
|
Solid Clouds hf
IC:SOLID
|
N/A |
|
Harvest Gold Corporation
PINK:HVGDF
|
-0.034x |
|
Myeco Group Ltd
F:MZ60
|
N/A |
|
DIANOMI PLC LS -002
F:3NJ
|
N/A |
|
Hindprakash Industries Limited
NSE:HPIL
|
0.004x |
|
SVP GLOBAL TEXTILES LIMITED
NSE:SVPGLOB
|
-0.001x |
|
Libstar Holdings Ltd
JSE:LBR
|
0.068x |
Annual Cash Flow Conversion Efficiency for STME (2012–2025)
The table below shows the annual cash flow conversion efficiency of STME from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-05-31 | $-1.25 Million | $-141.60K | 0.114x | -35.64% |
| 2024-05-31 | $-826.46K | $-145.90K | 0.177x | +54.70% |
| 2023-05-31 | $-2.39 Million | $-272.21K | 0.114x | -49.12% |
| 2022-05-31 | $-2.01 Million | $-450.59K | 0.224x | -36.93% |
| 2021-05-31 | $-1.58 Million | $-560.43K | 0.356x | -41.61% |
| 2020-05-31 | $-1.52 Million | $-925.84K | 0.609x | +250.99% |
| 2019-05-31 | $-1.77 Million | $-307.54K | 0.174x | -58.56% |
| 2018-05-31 | $-1.07 Million | $-449.43K | 0.419x | -35.07% |
| 2017-05-31 | $-1.17 Million | $-754.06K | 0.645x | +116.07% |
| 2016-05-31 | $-1.41 Million | $-421.57K | 0.298x | -35.56% |
| 2015-05-31 | $-684.07K | $-316.81K | 0.463x | -3.40% |
| 2014-05-31 | $-20.39K | $-9.78K | 0.479x | -92.91% |
| 2013-05-31 | $-1.87K | $-12.64K | 6.764x | +478.41% |
| 2012-05-31 | $10.77K | $-19.25K | -1.788x | -- |